Search Results - "Reeves, Karen R"

A randomized evaluation of the effects of six antipsychotic agents on QTc, in the absence and presence of metabolic inhibition by HARRIGAN, Edmund P, MICELI, Jeffrey J, ANZIANO, Richard, WATSKY, Eric, REEVES, Karen R, CUTLER, Neal R, SRAMEK, T. John, SHIOVITZ, Thomas, MIDDLE, Michelle

“…Many drugs have been associated with QTc prolongation and, in some cases, this is augmented by concomitant administration with metabolic inhibitors. The…”
Get full text

Varenicline, an alpha 4 beta 2 Nicotinic Acetylcholine Receptor Partial Agonist, vs Sustained-Release Bupropion and Placebo for Smoking Cessation: A Randomized Controlled Trial by Gonzales, David, Rennard, Stephen I, Nides, Mitchell, Oncken, Cheryl, Azoulay, Salomon, Billing, Clare B, Watsky, Eric J, Gong, Jason, Williams, Kathryn E, Reeves, Karen R

“…CONTEXT: The alpha 4 beta 2 nicotinic acetylcholine receptors (nAChRs) are linked to the reinforcing effects of nicotine and maintaining smoking behavior…”
Get full text

Effect of Maintenance Therapy With Varenicline on Smoking Cessation: A Randomized Controlled Trial by Tonstad, Serena, Tønnesen, Philip, Hajek, Peter, Williams, Kathryn E, Billing, Clare B, Reeves, Karen R, Varenicline Phase 3 Study Group, for the

“…CONTEXT The majority of cigarette smokers who achieve abstinence relapse within the first year and require many attempts before achieving permanent abstinence…”
Get full text

Varenicline, an α4β2 Nicotinic Acetylcholine Receptor Partial Agonist, vs Sustained-Release Bupropion and Placebo for Smoking Cessation: A Randomized Controlled Trial by Gonzales, David, Rennard, Stephen I, Nides, Mitchell, Oncken, Cheryl, Azoulay, Salomon, Billing, Clare B, Watsky, Eric J, Gong, Jason, Williams, Kathryn E, Reeves, Karen R, Varenicline Phase 3 Study Group, for the

“…CONTEXT The α4β2 nicotinic acetylcholine receptors (nAChRs) are linked to the reinforcing effects of nicotine and maintaining smoking behavior. Varenicline, a…”
Get full text

Efficacy of Varenicline, an α4β2 Nicotinic Acetylcholine Receptor Partial Agonist, vs Placebo or Sustained-Release Bupropion for Smoking Cessation: A Randomized Controlled Trial by Jorenby, Douglas E, Hays, J. Taylor, Rigotti, Nancy A, Azoulay, Salomon, Watsky, Eric J, Williams, Kathryn E, Billing, Clare B, Gong, Jason, Reeves, Karen R, Varenicline Phase 3 Study Group, for the

“…CONTEXT Varenicline, a partial agonist at the α4β2 nicotinic acetylcholine receptor, has the potential to aid smoking cessation by relieving nicotine…”
Get full text

Efficacy of Varenicline, an alpha 4 beta 2 Nicotinic Acetylcholine Receptor Partial Agonist, vs Placebo or Sustained-Release Bupropion for Smoking Cessation: A Randomized Controlled Trial by Jorenby, Douglas E, Hays, JTaylor, Rigotti, Nancy A, Azoulay, Salomon, Watsky, Eric J, Williams, Kathryn E, Billing, Clare B, Gong, Jason, Reeves, Karen R

“…CONTEXT: Varenicline, a partial agonist at the alpha 4 beta 2 nicotinic acetylcholine receptor, has the potential to aid smoking cessation by relieving…”
Get full text

Efficacy and tolerability of varenicline, an α4β2 nicotinic acetylcholine receptor partial agonist, in a 12-week, randomized, placebo-controlled, dose-response study with 40-week follow-up for smoking cessation in japanese smokers by NAKAMURA, Masakazu, OSHIMA, Akira, FUJIMOTO, Yoko, MARUYAMA, Nami, ISHIBASHI, Taro, REEVES, Karen R

Get full text

A double-blind study evaluating the long-term safety of varenicline for smoking cessation by Williams, Kathryn E., Reeves, Karen R., Billing, Clare B., Pennington, Ann M., Gong, Jason

“…ABSTRACT Objective: We assessed the safety of long-term varenicline administration for smoking cessation. Methods: In this randomized, double-blind,…”
Get full text

The efficacy and safety of varenicline for smoking cessation using a flexible dosing strategy in adult smokers: a randomized controlled trial by Niaura, Raymond, Hays, J. Taylor, Jorenby, Douglas E., Leone, Frank T., Pappas, John E., Reeves, Karen R., Williams, Kathryn E., Billing, Clare B.

“…ABSTRACT Objective: To determine whether self-regulated flexible dosing with varenicline tartrate is safe and effective for smoking cessation. Research design…”
Get full text

Intramuscular (IM) ziprasidone 20 mg is effective in reducing acute agitation associated with psychosis: a double-blind, randomized trial by DANIEL, David G, POTKIN, Steven G, REEVES, Karen R, SWIFT, Rachel H, HARRIGAN, Edmund P

“…Intramuscular (IM) conventional antipsychotics and/or benzodiazepines are effective in the short-term treatment of acutely agitated psychotic patients but may…”
Get full text

Intramuscular ziprasidone, 2 mg versus 10 mg, in the short-term management of agitated psychotic patients by LESEM, Michael D, ZAJECKA, John M, SWIFT, Rachel H, REEVES, Karen R, HARRIGAN, Edmund P

“…There is a clear need for effective, well-tolerated intramuscular (i.m.) agents for the acute control of agitated psychotic patients. Currently used agents,…”
Get full text

Ziprasidone in the short-term treatment of patients with schizoaffective disorder : Results from two double-blind, placebo-controlled, multicenter studies by KECK, Paul E, REEVES, Karen R, HARRIGAN, Edmund P

“…This study assessed the efficacy of ziprasidone for the treatment of schizoaffective disorder. Data were taken from subsets of patients with schizoaffective…”
Get full text

Comment: Oral Varenicline for Smoking Cessation by Gonzales, David, Rennard, Stephen I, Jorenby, Douglas E, Reeves, Karen R

Get full text

Ziprasidone 80 mg/day and 160 mg/day in the Acute Exacerbation of Schizophrenia and Schizoaffective Disorder: A 6-Week Placebo-Controlled Trial by Daniel, David G, Zimbroff, Dan L, Potkin, Steven G, Reeves, Karen R, Harrigan, Edmund P, Lakshminarayanan, Mani

“…In this double-blind study, patients with an acute exacerbation of schizophrenia or schizoaffective disorder were randomized to receive either ziprasidone 80…”
Get full text

Bees in SE Asia by REEVES, KAREN R, ANDERSON, WILLIAM H

Get full text

Efficacy and tolerability of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, in a 12-week, randomized, placebo-controlled, dose-response study with 40-week follow-up for smoking cessation in Japanese smokers by Nakamura, Masakazu, Oshima, Akira, Fujimoto, Yoko, Maruyama, Nami, Ishibashi, Taro, Reeves, Karen R

“…Varenicline, a selective alpha4beta2 nicotinic acetylcholine receptor partial agonist, has been developed specifically for smoking cessation. In Japan, 39.3%…”
Get full text

Efficacy and tolerability of varenicline, an [alpha]4[beta]2 nicotinic acetylcholine receptor partial agonist, in a 12-week, randomized, placebo-controlled, dose-response study with 40-week follow-up for smoking cessation in Japanese smokers by Nakamura, Masakazu, Oshima, Akira, Fujimoto, Yoko, Maruyama, Nami, Ishibashi, Taro, Reeves, Karen R

“…Abstract Varenicline, a selective α4β2 nicotinic acetylcholine receptor partial agonist, has been developed specifically for smoking cessation. In Japan, 39.3%…”
Get full text

Efficacy and tolerability of varenicline, an α 4β 2 nicotinic acetylcholine receptor partial agonist, in a 12-week, randomized, placebo-controlled, dose-response study with 40-week follow-up for smoking cessation in Japanese smokers by Nakamura, Masakazu, Oshima, Akira, Fujimoto, Yoko, Maruyama, Nami, Ishibashi, Taro, Reeves, Karen R.

“…Abstract Varenicline, a selective α 4β 2 nicotinic acetylcholine receptor partial agonist, has been developed specifically for smoking cessation. In Japan,…”
Get full text

Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial by Gonzales, David, Rennard, Stephen I, Nides, Mitchell, Oncken, Cheryl, Azoulay, Salomon, Billing, Clare B, Watsky, Eric J, Gong, Jason, Williams, Kathryn E, Reeves, Karen R

“…The alpha4beta2 nicotinic acetylcholine receptors (nAChRs) are linked to the reinforcing effects of nicotine and maintaining smoking behavior. Varenicline, a…”
Get full text

Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial by Jorenby, Douglas E, Hays, J Taylor, Rigotti, Nancy A, Azoulay, Salomon, Watsky, Eric J, Williams, Kathryn E, Billing, Clare B, Gong, Jason, Reeves, Karen R

“…Varenicline, a partial agonist at the alpha4beta2 nicotinic acetylcholine receptor, has the potential to aid smoking cessation by relieving nicotine withdrawal…”
Get full text